Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Suvorexant · 1 trial · 2 indications
Emax for drug liking VAS will be reported. Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment). It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking).
| Arm | Type | Description |
|---|---|---|
| Qualification Phase: Treatment Sequence YXZ | EXPERIMENTAL | Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days. |
| Qualification Phase: Treatment Sequence ZYX | EXPERIMENTAL | Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days. |
| Qualification Phase: Treatment Sequence XZY | EXPERIMENTAL | Participants will receive Treatment X in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days. |
| Qualification Phase: Treatment Sequence YZX | EXPERIMENTAL | Participants will receive Treatment Y in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days. |
| Qualification Phase: Treatment Sequence ZXY | EXPERIMENTAL | Participants will receive Treatment Z in qualification period 1, followed by Treatment X in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during qualification phase. Each treatment will be separated by washout of at least 3 days. |
| Qualification Phase: Treatment Sequence XYZ | EXPERIMENTAL | Participants will receive Treatment X in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment Z in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days. |
| Treatment Phase: Treatment Sequence ABFCED | EXPERIMENTAL | Participants will receive a single oral dose of placebo (Treatment A) in treatment period 1, followed by single oral dose of suvorexant (Treatment B) in treatment period 2, single oral Dose 3 of seltorexant (Treatment F) in treatment period 3, single oral dose of zolpidem (Treatment C) in treatment period 4, single oral Dose 2 of seltorexant (Treatment E) in treatment period 5 and then a single oral Dose 1 of seltorexant (Treatment D) in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days. |
| Treatment Phase: Treatment Sequence BCADFE | EXPERIMENTAL | Participants will receive Treatment B in treatment period 1, followed by Treatment C in treatment period 2, Treatment A in treatment period 3, Treatment D in treatment period 4, Treatment F in treatment period 5 and then Treatment E in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days. |
| Treatment Phase: Treatment Sequence CDBEAF | EXPERIMENTAL | Participants will receive Treatment C in treatment period 1, followed by Treatment D in treatment period 2, Treatment B in treatment period 3, Treatment E in treatment period 4, Treatment A in treatment period 5 and then Treatment F in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days. |
| Treatment Phase: Treatment Sequence DECFBA | EXPERIMENTAL | Participants will receive Treatment D in treatment period 1, followed by Treatment E in treatment period 2, Treatment C in treatment period 3, Treatment F in treatment period 4, Treatment B in treatment period 5 and then Treatment A in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days. |
| Treatment Phase: Treatment Sequence: EFDACB | EXPERIMENTAL | Participants will receive Treatment E in treatment period 1, followed by Treatment F in treatment period 2, Treatment D in treatment period 3, Treatment A in treatment period 4, Treatment C in treatment period 5 and then Treatment B in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days. |
| Treatment Phase: Treatment Sequence FAEBDC | EXPERIMENTAL | Participants will receive Treatment F in treatment period 1, followed by Treatment A in treatment period 2, Treatment E in treatment period 3, Treatment B in treatment period 4, Treatment D in treatment period 5 and Treatment C in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days. |
| Name | Type | Description |
|---|---|---|
| Suvorexant | DRUG | Suvorexant will be administered orally as per assigned treatment sequence. |
| Zolpidem | DRUG | Zolpidem will be administered orally as per assigned treatment sequence. |
| Seltorexant | DRUG | Seltorexant will be administered orally as per assigned treatment sequence. |
| Placebo | DRUG | Placebo will be administered orally as per assigned treatment sequence. |
Inclusion Criteria: * Be a current, recreational, not physically dependent, drug user * Participant must be medically stable * All female participants must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 of...
Suvorexant is an investigational small molecule being studied in healthy, non-dependent, recreational sedative users. It is being evaluated in the context of abuse potential research, specifically in a clinical trial that compares it to seltorexant and zolpidem. The drug is not approved and remains in clinical development.
Suvorexant is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research on this investigational small molecule in the United States.
Suvorexant is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its abuse potential in healthy, non-dependent, recreational sedative users.
Suvorexant has one completed Phase 1 clinical trial registered as NCT05106153. This study, titled 'A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem,' enrolled 127 participants in the United States. The trial was randomized, double-blind, and controlled.
No, Suvorexant is not the same as seltorexant. They are distinct drugs that were compared in a clinical trial. The study NCT05106153 evaluated the abuse potential of seltorexant relative to suvorexant and zolpidem, indicating these are separate investigational compounds.